NCT01202695View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Anthrax
Interventions
DRUG

AVP-21D9

intravenously, single dose

DRUG

Placebo

Placebo comparator

Trial Locations (1)

78209

ICON Development Solutions, San Antonio

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Emergent BioSolutions

INDUSTRY